Table 3.
TNBC patients treated by chemotherapy with or without platinum.
| Study | Study design | Setting | Outcome | With platinum | Without platinum | P value |
|---|---|---|---|---|---|---|
| Fan(2012)76 | Phase II | Metastatic | ORR | 63.0% | 15.4% | 0.001 |
| PFS | 10.9 m | 4.8 m | < 0.001 | |||
| OS | 32.8 m | 21.5 m | 0.027 | |||
| TBCRC001/Carey(2012)77 | Phase II | Metastatic | ORR | 17.0% | 6.0% | NA |
| PFS | 2.1 m | 2.6 m | NA | |||
| OS | 10.4 m | 7.5 m | NA | |||
| CALGB 40603/Sikov (2015)65 | Phase II | Neo-adjuvant | pCR | 60.0% | 44.0% | 0.0018 |
| GeparSixto/VonMinckwitz(2014)64 | Phase II | Neo-adjuvant | pCR | 53.2% | 36.9% | 0.005 |
| Villarreal-Garza(2014)78 | Retrospective | Adjuvant | OS | 14.5 m | 10 m | 0.041 |
| TnT/Tutt(2015)69 | Phase III | Adjuvant | ORR | 31.4% | 35.6% | 0.44 |
| PFS | 3.1 m | 4.5 m | 0.29 | |||
| OS | 12.4 m | 12.3 m | 0.31 | |||
| WSG-ADAPT/Gluz(2015)79 | Phase II | Neo-adjuvant | pCR | 49.2% | 25.0% | 0.006 |
| CBCSG006/Hu(2015)68 | Phase III | Adjuvant | PFS | 7.73 m | 6.47 m | NA |
NA: Not available. ORR: overall response rate. PFS: progression-free survival. OS: overall survival. pCR: pathologic complete response.